Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2003-12-09
2011-11-01
Ford, Vanessa L (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S247100, C424S167100, C424S239100, C424S093410, C514S018600
Reexamination Certificate
active
08048423
ABSTRACT:
Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.
REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5562907 (1996-10-01), Arnon
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6139845 (2000-10-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6358926 (2002-03-01), Donovan
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6447787 (2002-09-01), Gassner et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6477410 (2002-11-01), Henley et al.
patent: 2004/0001865 (2004-01-01), Naumann
patent: 2004/0087893 (2004-05-01), Kwon
patent: 2005/0260231 (2005-11-01), Brin et al.
patent: 2006/0153876 (2006-07-01), Sanders
patent: 0 845 267 (1998-06-01), None
patent: 0845267 (1998-06-01), None
patent: WO 00/24419 (1999-10-01), None
patent: WO 03/011333 (2003-02-01), None
Jenzer, G et al., Neurology, vol. 25, pp. 150-153, Feb. 1975.
Heckman, M., Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study, 2002, American Academy of Dermatology, 46, 617-9.
Dictionary Definition Print Preview.
Dictionary Definition Print Preview; Encarta® World English Dictionary [North American Edition] © & (P)2004 Microsoft Corporation. All rights reserved. Developed for Microsoft by Bloomsbury Publishing Plc.
Definition of Neuroma, Wikipedia (http://en.wikipedia.org/wiki
euromas).
Allergan, pp. 1-4, http://www.allergan.com/download/BotoxPl.pdf.
What is Hyperkeratosis (Health A-Z- www.everydayhealth.com; accessed May 19, 2010).
Seborrheic Keratosis (eMedicine Dermatology-www.emedicine.medscape.com; accessed May 19, 2010).
Gibbs et al. (BJM, 2002; 325: 1-8).
Hammertoe (no date) American College of Foot and Ankle Surgeons, 2 pages.
Stulberg et al., Am Fam Physician, 2003; 68: 1955-60.
Stulberg et al., Am Fam Physician, 2003; 68: 1963-80.
Andreadis S., et al.,Keratinocyte growth factor induces hyperproliferation and delays differentiation in a skin equivalent model system, FASEB J. Apr. 2001;15(6):898-906.
Aoki K., et al,Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing, Cephalalgia Sep. 2003;23(7):649.
U.S. Appl. No. 10/194,805, filed Jul. 11, 2002, Donovan, Stephen.
Arredondo J., et al.,Central role of alpha7 nicotinic receptor in differentiation of the stratified squamous epithelium, J Cell Biol. Oct. 28, 2002;159(2):325-36.
Asahina A., et al.,Specific induction of cAMP in Langerhans cells by calcitonin gene-related peptide: relevance to functional effects, Proc Natl Acad Sci U S A. Aug. 29, 1995;92(18):8323-7.
Bigalke H., et al.,Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture, Brain Research 360;318-324:1985.
Bigalke H., et al.,Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord, Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981.
Binz T. et al.,The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins, J Biological Chemistry 265(16);9153-9158:1990.
Brem, H., et al,Placebo-Controlled Trial of Safety and Efficacy of Intraoperative Controlled Delivery by Biodegradable Polymers of Chemotherapy for Recurrent Gliomas, Lancet 345;1008-1012:1995.
Chen W., et al.,Tropic interactions between sensory nerves and their targets, Journal of Biomedical Science. 1999;6(2):79-85.
Chiang H-Y, et al.,Regional difference in epidermal thinning after skin denervation, Exp Neurol 1998;154(1):137-45.
Chien., et al., (2001)Quantitative pathology of cutaneous nerve terminal degeneration in the human skin, Acta Neuropathologica 102:455-461.
Fung L. K. et al.,Pharmacokinetics of Interstitial Delivery of Carmustine 4-Hydroperoxycyclophosphamide and Paclitaxel From a Biodegradable Polymer Implant in the Monkey Brain, Cancer Research 58;672-684:1998.
Gonelle-Gisprt et al.;Snap -25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion; Biochem-J 1;339 (pt 1):159-65:1999.
Grando S.,Biological functions of keratinocyte cholinergic receptors, J Investig Dermatol Symp Proc. Aug. 1997;2(1):41-8.
Grando S., et al.,Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation. Invest Dermatol. 1996.
Grando S., et al.,Human keratinocytes synthesize, secrete, and degrade acetylcholineJ Invest Dermatol. Jul. 1993;101(1):32-6.
Grando S., et al.,Keratinocyte muscarinic acetylcholine receptors: immunolocalization and partial characterization, J Invest Dermatol. Jan. 1995;104(1):95-100.
Griffin J., et al., Axonal degeneration and disorders of the axonal cytoskeleton. In: Waxman S., et al.,The Axon. New York: Oxford University Press, 1995:375-390.
Habermann E., et al.,Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain, J Neurochem 51(2);522-527:1988).
Habermann E.,Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate, Experientia 44;224-226:1988.
Habermann, E.; I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord;Nauny-Schmiedeberg's Arch. Pharmacol. 1974; 281, 47-56.
Harrison's Principles of Internal Medicine(1998), edited by Anthony Fauci et al., 14th edition, published by McGraw Hill.
Hokfelt T.,Neuropeptides in perspective : The last ten years, Neuron 1991; 7: 867-879.
Hosoi J., et al.,Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide, Nature. May 13, 1993;363(6425):159-63.
Hsieh S., et al.,Epidermal denervation and its effects on keratinocytes and Langerhans cells, J Neurocytol. Sep. 1996;25(9):513-24.
Hsieh S., et al.,Modulation of keratinocyte proliferation by skin innervation. Journal of Investigative Dermatology, 1999;113(4):579-86.
Hsieh S., et al.,Pathology of nerve terminal degeneration in the skin, Journal of Neuropathology & Experimental Neurology. 2000;59(4):297-307.
Hsieh S., et al.,Skin Innervation and Its Effects on the Epidermis, J Biomed Sci. 1997;4(5):264-268.
Huang et al.;Influence of Cutaneous Nerves on Keratinocyte Proliferation and Epidermal Thickness in Mice; Neuroscience. 1999;94(3):965-73.
Inaba N., et al.,Capsaicin-induced calcitonin gene-related peptide release from isolated rat stomach measured with a new chemiluminescent enzyme immunoassay, Jpn J Pharmacol. Nov. 1996;72(3):223-9.
Jankovic J. et al.,Therapy With Botulinum Toxin, Marcel Dekker, Inc., (1994), p. 5, 150.
Johnson M.,Synaptic glutamate release by postnatal rat serotonergic neurons in microculture, Neuron 1994; 12: 433-442.
Kaneko T., et al.,Immunohistochemical demonstration of glutaminase in catecholaminergic and serotonergic neurons of rat brain, Brain Res. 1990; 507: 141-154.
Kasakov L., et al.,Direct evidence for concomitant release of noradrenaline, adenosine 5′-triphosphate and neuropeptide Y from sympathetic nerve supplying the guinea-pig vas deferens. J. Auton. Nerv. Syst. 1988; 22: 75-82.
Katsambas A., et al.,Cutaneous diseases of the foot: Unapproved treatments, Clin Dermatol Nov.-Dec. 2002;20(6):689-699.
Ko M., et al.,Cutaneous nerve degeneration induced by acrylamide in mice, Neuroscience Letters.(2000)293(3):195-8.
Komuves et al., Epidermal Expression of the Full-Length Extracellular Calcium-sensing Receptor is Required for Normal Keratinocyte Differentiation; J Cell Physiol. Jul. 2002;192(1):45-54.
Krnjevic K.,Central cholinergic mechanisms and function. Prog Brain Res. 1993;98:285-92.
Kupfermann I.;Functional studies of cotransmission
Allergan Inc.
Condino Debra
Ford Vanessa L
Gibson Hal
Tongue Lakia
LandOfFree
Botulinum toxin therapy for skin disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Botulinum toxin therapy for skin disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Botulinum toxin therapy for skin disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4286183